PIK3CA and biliary tract neoplasm: Genetic alterations, including mutations and/or amplifications, which activate the PI3K-AKT-mTOR pathway have been successfully targeted by Everolimus in advanced biliary tract cancer and heavily pretreated metastatic gastric cancer [60,61].